Delivery Order SPE2DB20D1004-SPE2DB25FNJMK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Rytary ER (carbidopa/levodopa extended-release) 36.25 mg-145 mg capsules in a quantity of 100 units, valued at $5,499.64. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July...
- The Defense Logistics Agency awarded a delivery order valued at $2,102.87 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg–195 mg capsules (100 count) on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $6,559.33 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of RYTARY ER 36.25 mg–145 mg capsules (100-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,796.99 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg-195 mg capsules (100-count units). This contract represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and was awarded on July 24, 2025, without any set-aside designation. The award was executed through open competition, reflecting the contractor's capability to meet federal pharmaceutical procurement requirements. Performance...
- The Defense Logistics Agency awarded a delivery order valued at $3,373.08 to AmerisourceBergen Drug Corp for RYTARY ER 36.25 mg-145 mg capsules (100 count) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and is being performed at the contractor's Conshohocken, Pennsylvania location. RYTARY is a specialized neurological medication used in the treatment of Parkinson's disease, reflecting the Defense...
- The Defense Logistics Agency awarded a $11,176.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of RYTARY ER 23.75 MG-95 MG, a pharmaceutical product used in the treatment of Parkinson's disease. The contract was awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $4,956.93 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of RYTARY ER 23.75 mg-95 mg capsules (100-count units). The order, which represents no set-aside designation and is due for completion by August 11, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen Drug Corp's larger Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,011.38 by the Defense Logistics Agency (DLA) on July 18, 2025, for the supply of RYTARY ER (carbidopa-levodopa extended-release) 48.75 mg-195 mg capsules in a quantity of 100 units. This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of July 21, 2025. The contract carries no set-aside designation, indicating open competition among qualified vendors. AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $13,503.12 to AmerisourceBergen Drug Corp for RYTARY ER 23.75 mg-95 mg capsules (100-count supply) on August 8, 2025, with completion expected by August 11, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RYTARY is a combination medication used in the treatment of Parkinson's...
- The Defense Logistics Agency awarded a $6,963.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rytary ER 48.75 mg-195 mg capsules (100-count containers). This is a non-set-aside competitive award with an ultimate completion date of August 1, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Rytary is a combination levodopa/carbidopa extended-release medication used to treat...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNJMKDelivery Order
The Defense Logistics Agency awarded a $3,565.50 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of RYTARY ER (extended-release carbidopa-levodopa) 36.25 mg-145 mg capsules in a quantity of 100 units. The delivery order is issued under a firm fixed-price contract with an ultimate completion date of July 21, 2025, and will be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award includes no set-aside designation and was awarded competitively. This delivery order is issued as a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. RYTARY ER is a neurological medication used for Parkinson's disease management, consistent with AmerisourceBergen's extensive portfolio of specialty and brand-name pharmaceuticals delivered through the federal medical supply chain to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/18/25 |